| Literature DB >> 29519960 |
Min Zhang1, Min Shi2, Yan Zhao2.
Abstract
Whether serum copper levels were higher in patients with cervical cancer than that in controls was controversial. Hence, we conducted the present study to explore the relationship between serum copper levels and cervical cancer. We searched PubMed, WanFang, and China National Knowledge Internet (CNKI) for relevant studies before November 30, 2017. Standardized mean difference (SMD) and 95% confidence interval (CI) were used to combine results across studies using the random-effect model. A total of 14 publications involving 747 patients with cervical cancer and 1014 controls were eligible through inclusion criteria. In comparison with controls, serum copper levels were significantly higher in patients with cervical cancer [summary SMD = 1.35; 95%CI: 0.10-2.59], with significant heterogeneity (I2 = 98.8%; P<0.001) was found. Significant association was also found among Asian populations [summary SMD = 1.39; 95%CI: 0.06-2.71]. The association was positive in subgroup analysis of population-based case-control studies (PBCC) [summary SMD = 1.64; 95%CI: 0.02-3.34], but not in hospital-based case-control studies (HBCC). Through a sensitivity analysis, we did not identify any single study to strongly influence the results of our serum copper levels and cervical cancer risk. No publication bias was found in our analysis. In conclusion, our study provided significant evidence of higher serum copper levels in patients with cervical cancer than in controls, suggesting that serum copper exposure was a risk factor on cervical cancer.Entities:
Keywords: Cervical cancer; Copper level; Meta-analysis; Serum
Mesh:
Substances:
Year: 2018 PMID: 29519960 PMCID: PMC6435553 DOI: 10.1042/BSR20180161
Source DB: PubMed Journal: Biosci Rep ISSN: 0144-8463 Impact factor: 3.840
Figure 1Flow diagram of the literature search
Characteristics of the included studies about serum copper levels and cervical cancer risk
| Study, year | Country | Age (range or Mean ± SD) | Study type | Study quality scores | Cervical cancer cases | Controls | ||
|---|---|---|---|---|---|---|---|---|
| Serum copper: mean ± SD | Serum copper: mean ± SD | |||||||
| Arumanayagam et al., 1993 [ | China | 58.7± 1.83 | HBCC | 7 | 57 | 19.1 ± 0.55 (μmol/l) | 24 | 18.2 ± 0.75 (μmol/l) |
| Cetinkaya et al., 1988 [ | Turkey | NA | PBCC | 7 | 9 | 1.69 ± 0.6 (μg/ml | 20 | 0.44 ± 0.46 (μg/ml) |
| Chen et al., 1990 [ | China | 25–70 | HBCC | 7 | 99 | 117.1 ± 14.6 (μg/ml) | 50 | 109.4 ± 17.4 (μg/ml) |
| Cunzhi et al., 2003 [ | China | 30–65 | PBCC | 6 | 40 | 19 ± 7 (μmol/l) | 50 | 14 ± 4 (μmol/l) |
| Fu et al., 2009 [ | China | 31–70 | PBCC | 7 | 74 | 18.96 ± 3.25 (μmol/l) | 180 | 15.78 ± 3.88 (μmol/l) |
| Grail et al., 1986 [ | U.K. | 25–60 | PBCC | 8 | 24 | 1.47 ± 0.26 (mg/l) | 21 | 1.25 ± 0.16 (mg/l) |
| Kim et al., 2003 [ | Korea | 35–74 | HBCC | 7 | 36 | 101.6 ± 5.25 (μg/dl) | 44 | 101.5 ± 5.47 (μg/dl) |
| Naidu et al., 2007 [ | India | 25–65 | PBCC | 8 | 30 | 117.4 ± 12.26 (μg%) | 30 | 109.7 ± 10.85 (μg%) |
| Ramteke et al., 2015 [ | India | 35–75 | PBCC | 8 | 50 | 156.9 ± 3.4 (μg/dl) | 50 | 107.2 ± 1.79 (μg/dl) |
| Subramanyam et al., 2013 [ | India | 30–75 | PBCC | 7 | 104 | 78.15 ± 2.8 (μg/dl) | 50 | 98.76 ± 2.43 (μg/dl) |
| Wang et al., 2010 [ | China | 25–60 | PBCC | 7 | 41 | 14.23 ± 3.15 (μmol/l) | 260 | 12.73 ± 2.56 (μmol/l) |
| Yu et al., 2016 [ | China | 36–65 | PBCC | 7 | 70 | 12.39 ± 2.1 (μmol/l) | 150 | 48.74 ± 6.5 (μmol/l) |
| Zhang et al., 1996 [ | China | 32–61 | PBCC | 6 | 55 | 24.93 ± 6.05 (μmol/l) | 35 | 19.31 ± 2.46 (μmol/l) |
| Zhang et al., 2015 [ | China | 32–70 | PBCC | 7 | 58 | 50.9 ± 4.5 (μmol/l) | 50 | 10.3 ± 4 (μmol/l) |
Abbreviations: HBCC, hospital-based case–control study; PBCC, population-based case–control study.
Figure 2Forest plot of SMD with corresponding 95%CI of studies about serum copper levels and cervical cancer risk
Figure 3Begg’s funnel plot about the association between serum copper levels and cervical cancer risk